Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Acromegalic Cardiomyopathy
NCT04520646Unknown
- Sponsor
- Huashan Hospital
- Start
- Sep 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of empagliflozin in Acromegalic cardiomyopathy (ACM), sponsored by Huashan Hospital. Primary endpoint: Left Ventricular Mass Index at 6 months. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
Acromegalic cardiomyopathy (ACM)
Beyond the preview
Go deeper on NCT04520646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04520646.